Clinical trials: Androgens
Prostate Cancer
Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients
The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients.
- Trial name
- NCT05202340
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Prostate
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study
Although compelling evidence from laboratory studies suggests that androgens play a major role in prostate carcinogenesis, epidemiologic studies in humans (almost exclusively serologic studies) have been unable to confirm the…
- Trial name
- NCT00342433
- Where
- 7 sites in United States, China
- Volunteers
- 553 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured…
- Trial name
- VERACITY (NCT04844749)
- Testing
- VERU-111, Enzalutamide, Abiraterone
- Where
- 40 sites in United States
- Volunteers
- 105 people
- Sponsor
- Veru Inc.
Polycystic Ovary Syndrome (PCOS), Insulin Resistance Syndrome
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS).
- Trial name
- PCOSMG53 (NCT07094776)
- Testing
- No intervention (observational study)
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Havva Betül Bacak
Polycystic Ovary Syndrome
Effect of Meal Composition on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome
The primary objective is to determine if meals of different fat and fiber content affect postprandial plasma testosterone concentration in women with polycystic ovary syndrome.
- Trial name
- NCT00455338
- Testing
- Meal Composition
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Prostate Cancer
Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer
PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand.
- Trial name
- NCT07562438
- Testing
- 177Lu-P17-088
- Where
- China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) Translational Study
The goal of this translational study is to test the use of biomarkers in salvage treatment for prostate cancer after a previous operation to remove the prostate.
- Trial name
- RADICALS-TR (NCT06145958)
- Testing
- Luteinising Hormone-Releasing Factor Analogue
- Volunteers
- 2,585 people
- Sponsor
- University College, London
Adenocarcinoma of the Prostate, Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer.
- Trial name
- NCT00165399
- Testing
- Docetaxel, Estramustine, Casodex
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically…
- Conditions
- Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
- Trial name
- RADVAN (NCT07477626)
- Testing
- Androgen Deprivation Therapy (ADT), radiotherapy
- Where
- 13 sites in China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring…
- Trial name
- NCT02726009
- Testing
- Degarelix
- Where
- 19 sites in India
- Volunteers
- 230 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258284
- Testing
- capecitabine, docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC.
- Trial name
- NCT04191096
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 234 sites in United States, Australia and 27 more
- Volunteers
- 1,251 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Prostate Cancer
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
This is a clinical research study of an investigational (FDA IND-BB 10091) treatment of subjects with castration-resistant prostate cancer resistant to Taxanes (docetaxel, cabazitaxel) and evidence of disease progression on…
- Trial name
- NCT01174368
- Testing
- Cancer Macrobead placement in abdominal cavity
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- The Rogosin Institute
Prostatic Cancer
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten…
- Trial name
- UROCOR (NCT01284608)
- Where
- 33 sites in Spain
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Recurrent Prostate Cancer, Stage I Prostate Cancer
Cilengitide in Treating Patients With Prostate Cancer
This phase II trial is studying how well cilengitide works in treating patients with prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT00121238
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Polycystic Ovary Syndrome
The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women
This is a placebo controlled trial investigating the effect of 6 months atorvastatin 20mg/day therapy on androgens, glucose metabolism and inflammatory markers in women with PCOS.
- Trial name
- NCT01072097
- Testing
- Atorvastatin
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- University of Oulu
Prostate Adenocarcinoma, Stage IIA Prostate Cancer
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
This randomized phase II trial studies the side effects and how well giving leuprolide acetate or goserelin acetate works compared to observation in treating patients with high-risk prostate cancer who have undergone radical…
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00937768
- Testing
- Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Prostate Cancer Locally Advanced
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
This study evaluated long-term disease control and side effects of a moderately hypofractionated radiotherapy protocol for men with high-risk prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Locally Advanced, Prostatic Neoplams
- Trial name
- NCT07900555
- Testing
- Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation, Androgen Deprivation Therapy (ADT)
- Where
- Norway
- Volunteers
- 191 people
- Sponsor
- Haukeland University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.